SCHEMBL3474868

SCHEMBL3474868

CCc1cccc(NC(=O)c2ccccc2C(=O)c2ccc3nc(NC(=O)O)[nH]c3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.60
▸ BRAF P15056 5/20 0.60
▸ KDR P35968 2/20 0.51
▸ TEK Q02763 1/20 0.51
▸ LMNA P02545 4/20 0.50
▸ ABL1 P00519 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ CYP2C9 P11712 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ ABCC4 O15439 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ MAPT P10636 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ PKM P14618 1/20 0.49
▸ KLF5 Q13887 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20525589 0.92 RAF1 (0.70) RAF1BRAFKDRTEKLMNA
SCHEMBL2357955 0.89 RAF1 (0.63) RAF1BRAFKDRLMNAABL1
SCHEMBL3471881 0.87 RAF1 (0.59) RAF1BRAFKDRLMNAABL1
SCHEMBL3475822 0.87 RAF1 (0.59) RAF1BRAFKDRTEKLMNA
SCHEMBL2356348 0.87 RAF1 (0.59) RAF1BRAFKDRTEKLMNA
SCHEMBL3473662 0.87 RAF1 (0.59) RAF1BRAFKDRLMNAABL1
SCHEMBL1791971 0.86 RAF1 (0.64) RAF1BRAFKDRLMNAABL1
SCHEMBL1791715 0.86 RAF1 (0.59) RAF1BRAFKDRLMNAABL1
SCHEMBL1467321 0.85 RAF1 (0.48) RAF1BRAFKDRTEKLMNA
SCHEMBL2297139 0.84 RAF1 (0.57) RAF1BRAFKDRLMNAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
Send feedback